Literature DB >> 12604417

Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.

David Marin, Sarah Marktel, Nicola Foot, Marco Bua, John M Goldman, Jane F Apperley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12604417

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  6 in total

1.  Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.

Authors:  Paul A Carpenter; David S Snyder; Mary E D Flowers; Jean E Sanders; Theodore A Gooley; Paul J Martin; Frederick R Appelbaum; Jerald P Radich
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

2.  Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia.

Authors:  Yanmin Zhao; Yamin Tan; Gongqiang Wu; Lizhen Liu; Yingjia Wang; Yi Luo; Jimin Shi; He Huang
Journal:  Int J Hematol       Date:  2011-07-05       Impact factor: 2.490

3.  Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.

Authors:  Alfonso Quintás-Cardama; Fabio Pires De Souza Santos; Hagop Kantarjian; Susan O'Brien; Stefan Faderl; Ahmed Awais; Gautam Borthakur; Jorge Cortes
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

Review 4.  Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.

Authors:  Michael W N Deininger
Journal:  J Cancer Res Clin Oncol       Date:  2003-11-07       Impact factor: 4.553

5.  Imatinib plus Granulocyte Colony-Stimulating Factor in Chronic Myeloid Leukemia Patients Who Have Achieved Partial or Complete Cytogenetic Response while on Imatinib.

Authors:  Baijun Fang; Ling Mai; Ning Li; Yongping Song; Robert Chunhua Zhao
Journal:  Case Rep Oncol       Date:  2011-04-02

6.  Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Authors:  Martin Henkes; Heiko van der Kuip; Walter E Aulitzky
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.